Chimioradiothérapie des cancers de l’œsophage : revue critique de la littérature [Chemoradiation for oesophageal cancer: A critical review of the literature]

Détails

ID Serval
serval:BIB_3CB618748C66
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Chimioradiothérapie des cancers de l’œsophage : revue critique de la littérature [Chemoradiation for oesophageal cancer: A critical review of the literature]
Périodique
Cancer radiotherapie
Auteur(s)
Blais E., Vendrely V., Sargos P., Créhange G., Huguet F., Maingon P., Simon J.M., Bourdais R., Ozsahin M., Bourhis J., Clément-Colmou K., Belghith B., Proudhom Briois M.A., Gilliot O., Dujols J.P., Peyras A., Dupin C., Riet F.G., Canova C.H., Huertas A., Troussier I.
ISSN
1769-6658 (Electronic)
ISSN-L
1278-3218
Statut éditorial
Publié
Date de publication
02/2019
Peer-reviewed
Oui
Volume
23
Numéro
1
Pages
62-72
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Locally advanced oesophageal cancer treatment requires a multidisciplinary approach with the combination of chemotherapy and radiotherapy for preoperative and definitive strategy. Preoperative chemoradiation improves the locoregional control and overall survival after surgery for locally advanced oesophageal cancer. Definitive chemoradiation can also be proposed for non-resectable tumours or medically inoperable patients. Besides, definitive chemoradiation is considered as an alternative option to surgery for locally advanced squamous cell carcinomas. Chemotherapy regimen associated to radiotherapy consists of a combination of platinum derived drugs (cisplatinum or oxaliplatin) and 5-fluorouracil or a weekly scheme combination of carboplatin and paclitaxel according to CROSS protocol in a neoadjuvant strategy. Radiation doses vary from 41.4Gy to 45Gy for a preoperative strategy or 50 to 50.4Gy for a definitive treatment. The high risk of lymphatic spread due to anatomical features could justify the use of an elective nodal irradiation when the estimated risk of microscopic involvement is higher than 15% to 20%. An appropriate delineation of the gross tumour volume requires an exhaustive and up-to-date evaluation of the disease. Intensity-modulated radiation therapy represents a promising approach to spare organs-at-risk. This critical review of the literature underlines the roles of radiotherapy for locally advanced oesophageal cancers and describes doses, volumes of treatment, technical aspects and dose constraints to organs-at-risk.
Mots-clé
Chemoradiotherapy, Esophageal Neoplasms/pathology, Esophageal Neoplasms/therapy, Humans, Lymph Nodes/radiation effects, Neoadjuvant Therapy, Radiotherapy Dosage, Tumor Burden, Cancer de l’œsophage, Chemoradiation, Chimioradiothérapie, Chimiothérapie, Neoadjuvant therapy, Oesophageal cancer, Radiochemotherapy, Radiochimiothérapie, Radiotherapy, Radiothérapie, Traitement néoadjuvant
Pubmed
Web of science
Création de la notice
08/02/2019 17:29
Dernière modification de la notice
20/08/2019 13:32
Données d'usage